CAS NO: | 882366-16-7 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Name: SBI-115 CAS#: 882366-16-7 Chemical Formula: C14H13ClN2O4S Exact Mass: 340.0285 Molecular Weight: 340.778 | |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Technical Information | Synonym: SBI115; SBI 115; SBI-115 Chemical Name: 4-Pyrimidinecarboxylic acid, 5-chloro-2-(ethylsulfonyl)-, 3-methylphenyl ester InChi Key: IJPXOPBVXVPPEW-UHFFFAOYSA-N InChi Code: InChI=1S/C14H13ClN2O4S/c1-3-22(19,20)14-16-8-11(15)12(17-14)13(18)21-10-6-4-5-9(2)7-10/h4-8H,3H2,1-2H3 SMILES Code: O=C(C1=NC(S(=O)(CC)=O)=NC=C1Cl)OC2=CC=CC(C)=C2 |
In Vitro | SBI-115 (100 and 200 μM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes[1]. Cell Proliferation Assay[1] Cell Line: shRNA-transfected ADPKD cholangiocytes Concentration: 100 and 200 μM Incubation Time: 24 hours Result: Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocytes with TLCA. |
---|---|
Reference | Hepatology. 2017 Oct; 66(4):1197-1218. |